Sensitivity versus cost effectiveness in postoperative follow-up for XXXX .

@entity1 @entity5 @entity358 @entity3 @entity14 @entity1320
The incidence of @entity14 is increasing. Approximately 20% of @entity1 present with untreatable, disseminated disease. The remaining 80% are generally treated by intended curative resection. Unfortunately, about 40% of the Dukes B2 and C @entity1 will develop recurrent disease. Of these @entity1 , about one third will develop hepatic @entity3 , one fifth @entity358 , one fifth @entity1320 , one tenth retroperitoneal @entity3 , and one twentieth anastomotic recurrences. @entity5 @entity1 may have pelvic recurrence rates as high as one third. Unfortunately, only about one fifth of the Dukes B2 and C @entity1 will initially develop recurrences at only one site and are, thus, potentially curable. Indeed, when considering all @entity14 @entity1 , resectable recurrences will be detected in the liver in only 2%, regional recurrences in about 10%, in the lungs in 2%, anastomotic recurrences in less than 1%, and in the ovaries in 1%. In general, long-term survival can be achieved in about 30% of these @entity1 with salvage surgery. The goal of intensive follow-up programs has been to identify these sole site recurrences at an earlier, asymptomatic stage and thereby improve survival. Unfortunately this laudable goal has not been achieved. Intensive (and expensive) follow-up programs consistently achieve long-term survival in 0% to 4% of @entity1 . Reliance on symptoms, however, achieves remarkably similar end results.(ABSTRACT TRUNCATED AT 250 WORDS)
